publication date: Nov. 30, 2018

Conversation with The Cancer Letter Hyman: “This approval adds to the growing utility of sequencing in patients with cancer” David Hyman

David Hyman

Chief, Early Drug Development Service,  Memorial Sloan Kettering Cancer Center

Global principal investigator for a larotrectinib clinical trial. 

 

As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval. 

“As we speak, more than ten solid tumors now require some form of routine sequencing to guide the standard of care. I expect this trend to continue and the detection of TRK fusion-positive cancers will mirror the adoption of NGS testing primarily driven by clinical needs other than TRK detection, rather than guiding other standard therapy prescribing for these patients,” Hyman said.

 

Hyman spoke with Paul Goldberg, editor and publisher of The Cancer Letter.

 

Paul Goldberg:

This is really cool science, and it’s great to see that such things … Continue reading Hyman: “This approval adds to the growing utility of sequencing in patients with cancer”

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.